Artivion, Inc.'s (NYSE:AORT) Senior Vice President and General Counsel, Jean F. Holloway, has sold a total of 1,250 shares of the company's common stock, according to a recent SEC filing. The transaction, which took place on May 10, 2024, was executed at a price of $23.42 per share, resulting in a total value of $29,275.
This sale by a key executive is a routine disclosure, and it offers investors a glimpse into the trading activities of Artivion's insiders. Following the transaction, Holloway's ownership in the company stands at 167,482 shares of common stock, directly held.
Artivion, Inc., headquartered in Kennesaw, Georgia, is known for its specialization in surgical and medical instruments and apparatus. The company, formerly known as CryoLife Inc., operates within the healthcare sector and continues to be a significant player in its industry.
The stock transaction details provide insight for current and potential investors about the movements of company shares by its executives. Such information is often monitored closely as part of a broader investment strategy.
The transaction was carried out in accordance with regulatory guidelines, and the filing with the SEC ensures transparency for shareholders and the investing public. The price at which the shares were sold reflects the market value at the time of the transaction.
Investors and analysts often keep an eye on insider transactions as they may reflect the executives' confidence in the company's prospects. However, it is also not uncommon for executives to sell shares for personal financial management reasons, unrelated to their outlook on the company's future performance.
Artivion's stock, traded under the ticker AORT, continues to be an active element of the New York Stock Exchange, with executives like Holloway participating in the market alongside public investors.
InvestingPro Insights
Artivion, Inc. (NYSE:AORT) has seen significant movements in its stock price, with a substantial return of 58.24% over the past year, according to InvestingPro data. The company's market capitalization stands at $969.49 million, reflecting its presence and valuation within the healthcare sector. Despite this positive trend, the company's P/E ratio remains negative at -99.79, indicating that it has not reported positive net earnings over the last twelve months as of Q1 2024.
InvestingPro Tips highlight that Artivion has a history of raising its dividend for four consecutive years, suggesting a commitment to returning value to shareholders. Moreover, analysts are optimistic about Artivion's future, expecting net income to grow this year. This could be a signal to investors that the company's financial health may be on an upward trajectory.
For investors seeking a deeper analysis and more InvestingPro Tips, there are additional insights available on Artivion, which can be found by visiting InvestingPro's dedicated page for AORT. Interested investors can also use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking even more valuable information to guide their investment decisions. As of now, there are 15 more InvestingPro Tips listed for Artivion, Inc. on InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.